This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaminskas, E. Articles by Pazdur, R. Search for Related Content PubMed PubMed Citation Articles by Kaminskas, E. Articles by Pazdur, R.

FDA Commentary

FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza^TM) for Injectable Suspension

Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA

Correspondence: Edvardas Kaminskas, M.D., U.S. Food and Drug Administration, 5600 Fishers Lane, HFD-150, Rockville, Maryland 20857, USA. Telephone: 301-594-5753; Fax: 301-594-0499; e-mail: kaminskase{at}cder.fda.gov

On May 19, 2004, azacitidine (5-azacytidine; Vidaza^TM; Pharmion Corporation, Boulder, CO, http://www.pharmion.com) for injectable suspension received regular approval by the U.S. Food and Drug Administration (FDA) for the treatment of all subtypes of myelodysplastic syndrome (MDS). This report summarizes the basis for this approval. Effectiveness was demonstrated in one randomized, controlled trial comparing azacitidine administered s.c. with best supportive care (observation group) and in two single-arm studies, one in which azacitidine was administered s.c. and in the other in which it was administered i.v. The dose of azacitidine, 75 mg/m²/day for 7 days every 28 days, was the same in all three studies. In the randomized trial, study participants were well matched with respect to age, sex, race, performance status, MDS subtype, and use of transfusion during the 3 months before study entry. Patients in the observation arm were permitted by protocol to cross over to azacitidine treatment if their disease progressed according to prespecified criteria. During the course of the study, more than half of the patients in the observation arm did cross over to the azacitidine treatment arm. The primary efficacy end point was the overall response rate. Response consisted of complete or partial normalization of blood cell counts and of bone marrow morphology. The response rate in the azacitidine arm was about 16%; there were no responses in the observation arm. The response rates in the two single-arm studies were similar (13% and 19%). The responses were sustained, with median durations of 11 months and 17 months respectively. Responding patients who were transfusion dependent at study entry lost the need for transfusions. In addition, about 19% of patients had less than partial responses (termed improvement), and two-thirds of them became transfusion independent. Common adverse events associated with azacitidine treatment were gastrointestinal (nausea, vomiting, diarrhea, constipation, and anorexia), hematologic (neutropenia, thrombocytopenia), fevers, rigors, ecchymoses, petechiae, injection site events, arthralgia, headache, and dizziness. Liver function abnormalities occurred in 16% of patients with intercurrent hepatobiliary disorders and in two patients with previously diagnosed liver cirrhosis. Renal failure occurred in patients during sepsis and hypotension. There were no deaths attributed to azacitidine. Azacitidine, the first drug approved by the U.S. FDA for MDS, has a favorable safety profile and provides a clinical benefit of eliminating transfusion dependence and complete or partial normalization of blood counts and bone marrow blast percentages in responding patients.

Key Words. Azacitidine • Vidaza^TM • Myelodysplastic syndromes • Refractory Anemia • Leukemia

This article has been cited by other articles:

				T. Weiland, M. Weiller, G. Kunstle, and A. Wendel Sensitization by 5-Azacytidine toward Death Receptor-Induced Hepatic Apoptosis J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 107 - 115. [Abstract] [Full Text] [PDF]

				M.-R. Pan, H.-C. Chang, L.-Y. Chuang, and W.-C. Hung The Nonsteroidal Anti-Inflammatory Drug NS398 Reactivates SPARC Expression via Promoter Demethylation to Attenuate Invasiveness of Lung Cancer Cells Exp Biol Med, April 1, 2008; 233(4): 456 - 462. [Abstract] [Full Text] [PDF]

				H. K. Kuo, J. D. Griffith, and K. N. Kreuzer 5-Azacytidine Induced Methyltransferase-DNA Adducts Block DNA Replication In vivo Cancer Res., September 1, 2007; 67(17): 8248 - 8254. [Abstract] [Full Text] [PDF]

				G. J. Schiller, J. Slack, J. D. Hainsworth, J. Mason, M. Saleh, D. Rizzieri, D. Douer, and A. F. List Phase II Multicenter Study of Arsenic Trioxide in Patients With Myelodysplastic Syndromes J. Clin. Oncol., June 1, 2006; 24(16): 2456 - 2464. [Abstract] [Full Text] [PDF]

				J. R Kuykendall 5-Azacytidine and Decitabine Monotherapies of Myelodysplastic Disorders Ann. Pharmacother., October 1, 2005; 39(10): 1700 - 1708. [Abstract] [Full Text] [PDF]